On July 14, HCA Healthcare fell 3.06% in regular trading, trading at $393.84/share, with turnover of $362 million. The decline came amid a wave of price target cuts from major Wall Street firms, intensifying downward pressure on the stock.

Most recently, Mizuho cut its price target on HCA Healthcare to $525 from $585 while maintaining an outperform rating. Earlier, Barclays downgraded the stock to equal weight from overweight and slashed its target to $427 from $496. Stephens reduced its target to $500 from $530, and Cantor Fitzgerald lowered its target to $525 from $588. The FactSet consensus mean price target has fallen from approximately $546 at the start of the year to around $492.60 currently.

The broader Health Care Facilities sector was under pressure, with Tenet Healthcare down 3.89%, Universal Health down 1.58%, and Acadia Healthcare down 1.41%. The target price reductions follow HCA's Q1 results that showed a lack of typical seasonal lift in admissions amid declines in respiratory activity, with management estimating an approximately $180 million negative impact on adjusted EBITDA from mild respiratory season and winter storms.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)